Some embodiments include a system. The system can comprise an energy source supply hub and an energy source supply appliance. The energy source supply hub can comprise a hub energy source supply system and a hub vehicle configured to transport the hub energy source supply system. Further, the hub energy source supply system can comprise a hub energy source supply subsystem configured to receive an energy source. Meanwhile, the energy source supply appliance can comprise an appliance energy source supply system and an appliance vehicle configured to transport the appliance energy source supply system. Further, the appliance energy source supply system can comprise an appliance energy source supply subsystem configured to receive the energy source from the hub energy source supply subsystem and to make available the energy source received to a receiver vehicle. Other embodiments of related systems, devices, and methods also are provided.

A compound according to formula IIa, which is (S,Z)-3,7-dimethylnon-6-en-1-ol and its use as fragrance.

##STR00001##

Compounds of formula (I), wherein A, R, W, Q, n, and m have the meaning according to the claims, can be employed, inter alia, for the treatment of tauopathies and Alzheimer's disease. ##STR00001##

The present invention refers to a process for the trans-selective hydroboration of internal alkynes and the so-obtained products. The inventive process makes use of a borane of the formula X.sup.1X.sup.2BH selected from the group of dialkyl boranes or di(alkoxy)boranes which are reacted with the internal alkynes in the presence of a cyclyopentadienyl-coordinated ruthenium catalyst.

An azeotropic or quasi-azeotropic composition including hydrogen fluoride, Z-3,3,3-trifluoro-1-chloropropene and one or more (hydro)halocarbon compounds including 1 to 3 carbon atoms. The (hydro) halocarbon compounds are preferably selected among tetrachlorofluoropropanes, trichlorodifluoropropanes, dichlorotrifluoropropanes, chlorotetrafluoropropanes, pentafluoropropanes, dichlorodifluoropropenes, chlorotrifluoropropenes and tetrafluoropropenes. A process for producing a main (hydro)halocarbon compound, including the formation of a mixture of compounds including hydrogen fluoride, Z-3,3,3-trifluoro-1-chloropropene and one or more other (hydro)halocarbon compounds, distillation of this mixture making it possible to collect, firstly, an azeotropic composition, and, secondly, at least one of the compounds of the mixture.

The present disclosure generally relates to methods for separating Δ.sup.8-THC, Δ.sup.9-THC, and related enantiomers using CO.sub.2-based chromatography.

A process for converting tertiary halogenated hydrocarbons in a tertiary halogenated hydrocarbon-containing stream to a corresponding unhalogenated or less-halogenated unsaturated hydrocarbon product with the release of hydrogen halide involves contacting the tertiary halogenated hydrocarbon with a sorbent-type dehydrohalogenation catalyst in a reaction zone and optionally passing a stripping gas through the reaction zone to remove vapor phase reaction products from the reaction zone. A process for removing a tertiary chlorinated hydrocarbon impurity from 1,3-dichloro-1-propene involves contacting a mixture containing the 1,3-dichloro-1-propene and the tertiary chlorinated hydrocarbon impurity with a dehydrochlorination catalyst effective to catalyze a conversion of the tertiary chlorinated hydrocarbon impurity to a corresponding unchlorinated or less-chlorinated unsaturated hydrocarbon and hydrogen chloride and distilling the 1,3-dichloro-1-propene to produce a purified cis-1,3-dichloro-1-propene fraction and a purified trans-1,3-dichloro-1-propene fraction.

The present invention relates to compounds that may be used in the treatment of Parkinson's disease, anxiety, emesis, obsessive compulsive disorder, autism, neuroprotection, cancer, depression or diabetes type 2.

In one aspect, the invention provides a method for synthesizing a fatty olefin derivative. The method includes: a) contacting an olefin according to Formula I

##STR00001##

with a metathesis reaction partner according to Formula IIb

##STR00002##

in the presence of a metathesis catalyst under conditions sufficient to form a metathesis product according to Formula IIIb:

##STR00003##

and
b) converting the metathesis product to the fatty olefin derivative. Each R.sup.1 is independently selected from H, C.sub.1-18 alkyl, and C.sub.2-18 alkenyl; R.sup.2b is C.sub.1-8 alkyl; subscript y is an integer ranging from 0 to 17; and subscript z is an integer ranging from 0 to 17. In certain embodiments, the metathesis catalyst is a tungsten catalyst or a molybdenum catalyst. In various embodiments, the fatty olefin derivative is a pheromone. Pheromone compositions and methods of using them are also described.

A method of making cyclobutane-1,2-diacid building blocks includes using trans-cinnamic acid in its beta form (head to head packing) and photodimerizing the trans-cinnamic acid to create cis-cyclobutane-1,2-dicarboxylic acid (CBDA-4).